Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients

This article was published in the following Dove Press journal:
International Journal of General Medicine
18 July 2012
Number of times this article has been viewed

Roger Wumba¹
Benjamin Longo-Mbenza²
Jean Menotti³,⁴
Madone Mandina⁵
Fabien Kintoki⁶
Nani Hippolyte Situakibanza⁷,⁸
Marie Kapepela Kakicha⁶
Josue Zanga⁶
Kennedy Mbanzulu-Makola⁴
Tommy Nseka⁵
Jean Pierre Mukendi¹
Eric Kendjo¹
Jean Sala¹
Marc Thellier⁵,⁷,⁸

¹Department of Tropical Medicine, Infectious and Parasitic Diseases, Department of Parasitology, University Clinic of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Congo;
²Faculty of Health Sciences, Walter Sisulu University, Eastern Cape, South Africa;³Laboratory of Parasitology and Mycology, Saint-Louis Hospital, Public Assistance-Hospitals of Paris, Paris, France;⁴Department of Internal Medicine, University Clinic of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Congo;⁵Department of Pediatrics, University Clinic of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Congo;⁶National Center for Malaria Research, AP-HP, CHU Pitie Salpêtrière, Paris, France;⁷Laboratory of Parasitology and Mycology, Pitie Salpêtrière Hospital, Public Assistance-Hospitals of Paris, Pierre and Marie Curie University, Paris, France

Background: The objective of this study was to determine the prevalence of intestinal parasites, with special emphasis on microsporidia and Cryptosporidium, as well as their association with human immunodeficiency virus (HIV) symptoms, risk factors, and other digestive parasites. We also wish to determine the molecular biology definitions of the species and genotypes of microsporidia and Cryptosporidium in HIV patients.

Methods: In this cross-sectional study, carried out in Kinshasa, Democratic Republic of the Congo, stool samples were collected from 242 HIV patients (87 men and 155 women) with referred symptoms and risk factors for opportunistic intestinal parasites. The analysis of feces specimen were performed using Ziehl–Neelsen stainings, real-time polymerase chain reaction (PCR), immunofluorescence indirect monoclonal antibody, nested PCR-restriction fragment length polymorphism, and PCR amplification and sequencing. Odds ratio (OR) and 95% confidence intervals were used to quantify the risk.

Results: Of the 242 HIV patients, 7.8%, 0.4%, 5.4%, 0.4%, 2%, 10.6%, and 2.8% had Enterocytozoon bieneusi, Encephalitozoon intestinalis, Cryptosporidium spp., Isospora belli, pathogenic intestinal protozoa, nonpathogenic intestinal protozoa, and helminths, respectively. We found five genotypes of E. bieneusi: two older, NIA1 and D, and three new, KIN1, KIN2, and KIN3. Only 0.4% and 1.6% had Cryptosporidium parvum and Cryptosporidium hominis, respectively. Of the patients, 36.4%, 34.3%, 31%, and 39% had asthenia, diarrhea, a CD4 count of <100 cells/mm³, and no antiretroviral therapy (ART), respectively. The majority of those with opportunistic intestinal parasites and C. hominis, and all with C. parvum and new E. bieneusi genotypes, had diarrhea, low CD4+ counts of <100 cells/mm³, and no ART. There was a significant association between Entamoeba coli, Kaposi sarcoma, herpes zoster, chronic diarrhea, and asthenia, and the presence of 28 cases with opportunistic intestinal parasites.

Conclusions: E. bieneusi and Cryptosporidium are becoming more prevalent in Kinshasa, Congo. Based on the findings, we recommend epidemiology surveillance and prevention by means of hygiene, the emphasis of sensitive PCR methods, and treating opportunistic intestinal parasites that may be acquired through fecal–oral transmission, surface water, normal immunity, rural area-based person–person and animal–human infection, and transmission of HIV. Therapy, including ART and treatment with fumagillin, is needed.

Keywords: diarrhea, Enterocytozoon bieneusi, Cryptosporidium hominis, Cryptosporidium parvum, risk factors, Africans
Introduction

Enteric opportunistic parasites are associated with HIV/AIDS, chronic diarrhea, education, occupation, residence in a slum, exposure to pets and animals, antiretroviral therapy (ART), use of public toilets, water, and practicing unsafe homosexual activity.1–20 The literature indicates that the prevalence of intestinal colonization due to microsporidia and Cryptosporidium are significantly higher among HIV-infected individuals with chronic diarrhea and CD4 lymphocyte counts of <200 cells/mm³.4,7,8,11,13,15,17,20

In the Democratic Republic of the Congo (DRC), our country, the role of emerging pathogens such as Enterocytozoon bieneusi and Cryptosporidium spp. in HIV-infected patients, with and without diarrhea, has been identified using standard parasitological methods, such as light microscopy, Ziehl–Neelsen staining, the Fungi-Fluor® Kit for Fungal Detection, modified trichrome tests, and traditional polymerase chain reaction (PCR).21,22 However, the lack of sensitive and specific real-time PCR, nested PCR, and PCR-restriction fragment length polymorphism (RFLP) in the DRC has resulted in a lack of epidemiologic, clinical, and immune data related to intestinal parasites in HIV patients. Therefore, the objective of the present study was to determine the prevalence of intestinal opportunistic parasites, with special emphasis on microsporidia and Cryptosporidium, as well their association with HIV symptoms, risk factors, and other digestive parasites, and the molecular biology definition of the species and the genotypes of microsporidia and Cryptosporidium in HIV patients. Humanitarian collaboration with French hospitals (Saint-Louis, Pitié Salpêtrière, and INSERM UMR-S 945, Paris) has helped us to perform molecular biology in this work.

Materials and methods

Study design

This descriptive and observational cross-sectional study took place between December 2009 and January 2012.

Ethical considerations

The institutional review boards and the Ethics Committee of the University of Kinshasa Faculty of Medicine approved the protocol of the study, which was conducted in compliance with the principles of the Helsinki Declaration II. The aim and the procedures of the study were explained to the participants and each participant (or a designated literate substitute, when necessary) signed an informed consent form.

Study setting

We randomly selected four main hospitals in Kinshasa, DRC: the Cliniques Universitaires de Kinshasa, which is a teaching hospital in the southwestern part of the city of Kinshasa, the General Referral Hospital of Kinshasa in central Kinshasa, the General Referral Hospital of Kintambo in the northeastern part of Kinshasa, and the Military Referral Hospital of Camp Kokolo in the western part of Kinshasa.

Patients and clinical specimens

We included 242 consecutive patients infected with HIV/AIDS. Epidemiologic, clinical, immune and laboratory data were collected from all participants.

Epidemiology data

Each participant was interviewed using a standardized, structured questionnaire to collect data regarding the prevalence of intestinal parasites (pooled, nonopportunistic, and opportunistic) and sociodemographic, environmental, and risk factors. The sociodemographic data were defined by gender, age, and socioeconomic status (low vs high by composite variables for education, occupation, and income). The environment was defined by the residence: rural, semirural, and urban areas. The risk factors for microsporidiosis and cryptosporidiosis included person–person infection by persons with chronic diarrhea via public toilets, ART, homosexual activities, through water storage, water pipes, swimming, and surface water; consumption of high-risk foods (fresh raw fruits and vegetables and food from street vendors); and zoonotic transmission routes (presence of specific domestic farm and pet animals in the home, such as dogs, pigs, goats, and chickens, and contact with droppings from these animals). We collected the risk-factor data prior to the interview and collection of the laboratory data.

Clinical spectrum

Medical students collected data regarding symptoms of the presence of HIV clinical manifestations, such as Kaposi sarcoma, herpes zoster, candidiasis, asthenia, and chronic diarrhea. We defined diarrhea as an average of ≥3 loose or liquid stools within a 24-hour period.

As defined by the World Health Organization,23 the four clinical stages of HIV/AIDS comprise stages 1–2 for pre-AIDS and stages 3–4 for AIDS.

Parasitological diagnosis

Samples and staining

Stool samples (one for each patient) were studied using optical microscopy (direct examination and specific stainings).
Stools were collected in a vial containing phosphate-buffered saline and stored in a refrigerator at 4°C before handling. Microscopic analysis of feces and the direct concentration method according to the protocol of Ritchie²⁵ were performed in the laboratory of the Department of Parasitology, University Clinics of Kinshasa. Ziehl–Neelsen staining (modified Henricksen–Pohlenz) was used for detecting Cryptosporidium sp.²⁵

**Species identification**

**Indirect immunofluorescence**

We used indirect immunofluorescence with monoclonal antibodies, which is an effective method for the diagnosing of microsporidiosis, for identification of *E. bieneusi* and *Encephalitozoon intestinalis*.²⁶

**Molecular methods**

**Extraction of DNA products**

DNA extraction was performed using a QIAmp DNA kit (QIAGEN, Courtaboeuf, France) in 50 µL of phosphate-buffered saline and divided into an aliquot (1 Eppendorf tube) and then stored at −20°C prior to analysis, according to the manufacturer’s instructions.

**Real-time PCR**

We carried out a real-time PCR for samples at the Saint Louis Hospital Parasitology mycology service in Paris, France, using a TaqMan® 7500 Real Time PCR System (Applied Biosystems, Foster City, CA) for identification of the two species (*E. bieneusi* and *E. encephalitozoon*).²⁷ The real-time PCR also served for identification of the genus *Cryptosporidium* for targeting a fragment of 145 bp 18 s rRNA gene, which is specific for three species (*Cryptosporidium parvum*, *Cryptosporidium hominis*, and *Cryptosporidium meleagridis*), according to the protocol of Fontaine et al.²⁸,²⁹ To make the PCR more specific and sensitive, two primers and one probe were used for each species.

**Cryptosporidium spp. by nested PCR and PCR-RFLP**

The nested PCR used two primer pairs amplifying a 179–271 bp 18s rRNA gene fragment.³⁰ Restriction assays were performed in a 30 µL volume with two units of restriction enzyme and 5 µL of PCR product per reaction. Mixes were incubated in a heating block. Digestion products were visualized under ultraviolet light after 2% agarose gel electrophoresis and SYBR Green I staining. The enzymes used were Taq1 (Roche-Boehringer, Mannheim, Germany) and Ase1 (New England Biolabs, Beverly, MA).³⁰

**PCR amplification of *E. bieneusi***

The standard method for determining the genotype of *E. bieneusi* was based on the DNA sequence of the internal transcribed spacer (ITS) region of the rRNA gene. Genotypic analysis of *E. bieneusi* isolates was performed by sequencing the ITS portion of the rRNA gene. On the basis of these results, a phylogenetic interpretation regarding the sources and routes of transmission of the different groups of *E. bieneusi* genotypes was proposed.³¹

**Nucleotide sequencing of the ITS region of the *E. bieneusi* rRNA gene**

*E. bieneusi* genotypes were analyzed by nucleotide sequencing of the ITS region of the rRNA gene. A PCR product of 508 bp, containing 122 bp of the small subunit rRNA, 243 bp of the ITS region, and 143 bp of the large-subunit rRNA, was generated from 19 samples, using the primers MSP-3 [5′-GGA ATT CAC ACC GCC CGT C (A/G)(C/T)TAT-3′] and MSP4B (5′-CCA AGC TTA TGC TTA AGT CCA GGG AG-3′), as described previously.³²,³³ PCR products were purified using a Concert Rapid PCR kit (Gibco-BRL, Gel Company Inc, San Francisco, CA) and sequenced in both directions using an ABI Big Dye Terminator kit (v 1.1) and an ABI 3100 automated sequencer (Applied Biosystems). The sequence accuracy was controlled by sequencing two PCR products from the same sample.

**Phylogenetic analysis**

The ITS sequences were obtained by comparing those from previously published records in GenBank using BLAST analysis (National Center for Biotechnology Information, Bethesda, MD). Multiple alignments of our new ITS nucleotide sequences and approximately 250 sequences were retrieved from GenBank (available by January 2012).

**Nucleotide sequence accession numbers**

Nucleotide sequences of the ITS region of the rRNA gene of one isolate for each genotype from DRC were deposited in the GenBank database. The accession numbers for the DRC isolates are JQ437573, JQ437574, and JQ437575 for the genotypes KIN1, KIN2, and KIN3, respectively.

**Statistical analysis**

Data were analyzed using the proportions (%) for categorical variables and means with standard deviations for continuous variables. Differences were compared using the chi-square test for proportions and the Student’s t-test for continuous variables.
Analysis of variance was used to compare means across more than two groups. Odds ratios (OR) were calculated with 95% confidence intervals (95% CI) using univariate analysis for potential risk factors (associated factors by contingency table) and logistic regression model (multivariate analysis) for independent determinants for opportunistic enteric parasites, after adjusting for confounding factors. A P value < 0.05 was considered statistically significant. All analyses were performed using Stata® software (v 11; StataCorp, College Station, TX) and SPSS software for Windows (v 19; IBM Corp, Armonk, NY).

Results
Patient characteristics
There were 242 participants in the study, 87 men (35.9%) and 155 women (64.1%), with a 2:1 women-to-men ratio. The mean age of the participants was 39.2 ± 11.8 years (range, 15–73 years).

Prevalence of gastrointestinal parasites
Table 1 summarizes the prevalence rates of pathogenic intestinal protozoa (2%), nonpathogenic intestinal protozoa (10.6%), and helminths (2.8%).

Prevalence of microsporidia and Cryptosporidium spp.
The real-time PCR reported prevalence rates of 8.2% (n = 20), 7.8% (n = 19), 0.4% (n = 1), and 5.4% (n = 13) for all microsporidia, E. bieneusi, E. intestinalis, and Cryptosporidium spp. among 242 stool specimens, respectively.

Analysis of E. bieneusi and Cryptosporidium spp. genotypes
Figure 1 shows isolates of five E. bieneusi strains yielded from the PCR product that were considered sufficient for the nucleotide sequencing of the ITS region of the rRNA gene. We reported the five different genotypes for E. bieneusi (two previously called NIA1 and D and three new ones) in Table 2.

PCR-RFLP products had 0.4% (n = 1) C. parvum and 1.6% (n = 4) had C. hominis among all 242 stool samples.

Clinical and immune profiles
Of the 242 participants, 88 (36.4%) had asthenia, 83 (34.3%) had diarrhea, and 75 (31%) had CD4 counts < 100 cell/mm³.

There was a significant association between asthenia (53.6%, n = 15; P = 0.04), chronic diarrhea (57.1%, n = 16; P = 0.007), Kaposi sarcoma (75%, n = 21; P < 0.0001), herpes zoster (64.3% n = 18; P < 0.001), CD4 count <100 cells/mm³ (53.6%, n = 15; P = 0.006), and the presence of opportunistic intestinal parasites (microsporidia + Cryptosporidium) in 28 patients. In addition, there was a significant relationship between digestive candidiasis, World Health Organization HIV stages, and the presence of microsporidia, E. bieneusi, and Cryptosporidium (results not shown).

Twelve (63.2%) of the 19 E. bieneusi cases had diarrhea; seven of the 13 Cryptosporidium spp. cases had chronic diarrhea; three of the C. hominis cases had chronic diarrhea, one C. parvum case had diarrhea, and one C. hominis case did not have chronic diarrhea among the five different species identified by PCR-RFLP. The patients with the three new genotypes designated by GenBank as KIN1, KIN2, and KIN3 suffered from chronic diarrhea. The patients with these new genotypes had CD4 levels of <200 cells/mm³.

Epidemiological data
Homosexual activity was not reported by the study population. There was a significant and negative association between the presence of opportunistic intestinal parasites (n = 28) and urbanization in the Kinshasa region (Figure 2).

The burden of opportunistic intestinal parasites decreased (P for trend = 0.023) with the highest, the intermediate, and the lowest rates in the rural, semiurban, and urban areas, respectively, in Kinshasa residences.

The other univariate risk factors for the presence of opportunistic intestinal parasites were a CD4 count < 100 cells/mm³, no ART, exposure to farm pigs, drinking and recreational surface water, and public toilets (Table 3). The decreasing but significant power of the association (OR) was for exposure to pigs, ART, public toilets, surface water, and a CD4 count < 100 cells/mm³. Three new genotypes KIN1, KIN2, and KIN3 were found from 5 species of E. bieneusi. From the four Cryptosporidium species, one was identified as C. parvum and three as C. hominis. The sociodemographic
data and food exposure were not associated with the presence of opportunistic intestinal parasites (results not shown).

After adjusting for Kinshasa residence, public toilets, and exposure to farm pigs in the multivariate analysis, only a CD4 count < 100 cells/mm$^3$, no ART, and exposure to surface water were identified as significant and independent determinants for the presence of opportunistic intestinal parasites (Table 4).

**Discussion**

The present study reports the epidemiological, clinical, immune, and molecular profiles of opportunistic and nonopportunistic intestinal parasites in HIV-infected individuals in the DRC, Central Africa. Microsporidia and *Cryptosporidium* spp. were the important etiologic agents identified using both older and new laboratory methods for the diagnosis of parasitic diseases.\(^{34}\)

In our African setting, the methods for the diagnosis of intestinal parasites in HIV/AIDS patients with chronic diarrhea have stagnated since 1981 until publication of our studies.\(^{21,22}\)

For many years, microscopy was the only method available for feces analysis. Further, indirect immunofluorescence with monoclonal antibodies was the only tool in the diagnosis of microsporidia before PCR began to be used in the DRC. Molecular-based approaches used in this study comprised extraction of DNA products: real-time PCR and nested PCR-RFLP. They were developed and applied for detecting microsporidia (*E. bieneusi* and *E. intestinalis*) and *Cryptosporidium* spp. in stool specimens from HIV-infected patients.

The burden of pathogenic intestinal protozoa (*Entamoeba histolytica/dispar* and *Giardia lamblia*), nonpathogenic intestinal protozoa (*Entamoeba coli, Endolimax nana*, and *Iodamoeba butschlii*), intestinal helminths (*Ascaris lumbricoides* and *Trichuris trichiura*), and opportunistic intestinal parasites (microsporidia, *Cryptosporidium* spp., and *Isospora belli*) in this study was lower than the prevalence of enteric parasites among HIV-individuals worldwide.\(^{1–22}\) The low prevalence of HIV/AIDS in the DRC\(^ {35}\) may explain the

<table>
<thead>
<tr>
<th>Number</th>
<th>PCR RT</th>
<th>PCR MSP3/MSP4B</th>
<th>Genotypes</th>
<th>% opportunistic intestinal parasites</th>
</tr>
</thead>
<tbody>
<tr>
<td>07</td>
<td><em>Eb</em></td>
<td>Positive</td>
<td>KIN1 JQ437573 (new)</td>
<td>Rural: 20</td>
</tr>
<tr>
<td>30</td>
<td><em>Eb</em></td>
<td>Positive</td>
<td>KIN2 JQ437574 (new)</td>
<td>Semi rural: 7.5</td>
</tr>
<tr>
<td>37</td>
<td><em>Eb</em></td>
<td>Positive</td>
<td>KIN3 JQ437575 (new)</td>
<td>Urban: 5.6</td>
</tr>
<tr>
<td>40</td>
<td><em>Eb</em></td>
<td>Positive</td>
<td>NIA1 (Espen et al(^ {21}), Wumba et al(^ {21}))</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td><em>Eb</em></td>
<td>Positive</td>
<td>D (Breton et al(^ {21}))</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2** Different genotypes for *Enteroctozaon bieneusi* (*Eb*) identified by sequencing

<Figure 1> Positive results from polymerase chain reaction (PCR)-nucleotide sequencing of the internal transcribed spacer region of the *Enterocytozoon bieneusi* (*Eb*) rRNA gene, samples 7, 30, 37, 40, and 63.

<Figure 2> Relationship between the presence of opportunistic intestinal parasites and residence in the Kinshasa region.
present rates of microsporidia, *E. bieneusi*, *E. intestinalis*, and *Cryptosporidium* spp.

The very high prevalence of HIV/AIDS in countries of Southern Africa, and homosexual activity in Western developed countries are reflected in the high prevalence (average 52%) of *Cryptosporidium* and microsporidia among HIV patients from Zimbabwe, South Africa, and Italy.

The expansion of the use of PCR techniques with HIV/AIDS patients in this study led to the identification of genotypes in microsporidia and *Cryptosporidium* spp. Microsporidia are single-celled, obligate intracellular parasites that are now reclassified from fungi. *E. bieneusi* was the most frequently used PCR-based method in this study. *E. bieneusi* is also the most common species reported to infect humans.

In this study, the genotypes NIA1 and D of *E. bieneusi* were present in two patients. Espern et al in 2007 and Wumba et al in 2010 reported the NIA1 genotype and Breton et al reported the D genotype in 2007. Our study is the first to report three new genotypes of *E. bieneusi*, referred to as KIN1, KIN2, and KIN3. The tropical Kinshasa environment-based discoveries of the new genotypes were specific for chronic diarrhea, low CD4 levels, and no ART. The present positive association between opportunistic intestinal infection, including the highest proportion of *E. bieneusi* and diarrhea, may exhibit adaptation to individual cell types, tropism of the epithelium of the small bowel and, the cryptic cells.

### Table 3 Risk factors for *Enterocytozoon bieneusi* (Eb)/*Cryptosporidium* spp. (Csp) infections among human immunodeficiency virus/acquired immunodeficiency syndrome patients (univariate analysis)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number tested</th>
<th>Number with Eb–Csp</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 count (cells/mm³) &lt; 100</td>
<td>75</td>
<td>15 (53.6)</td>
<td>2.49</td>
<td>66.05–166.81</td>
<td>0.006</td>
</tr>
<tr>
<td>No ART</td>
<td>95</td>
<td>20 (21.1)</td>
<td>4.70</td>
<td>1.90–11.40</td>
<td>0.0002</td>
</tr>
<tr>
<td>Domestic animals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Farm pigs</td>
<td>8</td>
<td>5 (10.7)</td>
<td>4.99</td>
<td>1.10–22.61</td>
<td>0.02</td>
</tr>
<tr>
<td>Sanitary conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surface water</td>
<td>36</td>
<td>8 (28.6)</td>
<td>2.66</td>
<td>1.06–6.68</td>
<td>0.03</td>
</tr>
<tr>
<td>Public toilets</td>
<td>98</td>
<td>19 (67.9)</td>
<td>3.53</td>
<td>1.49–8.33</td>
<td>0.002</td>
</tr>
</tbody>
</table>

**Note:** Values in parenthesis indicate the percentage.

**Abbreviations:** ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.

### Table 4 Independent determinants of opportunistic enteric parasites (multivariate analysis)

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Nonstandardized B</th>
<th>SE</th>
<th>Wald chi-squares</th>
<th>Exp(B) OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4, &lt; 100 vs ≥100 cells/mm³</td>
<td>1.519</td>
<td>0.500</td>
<td>9.211</td>
<td>4.60 (1.70–12.20)</td>
<td>0.002</td>
</tr>
<tr>
<td>ART, no vs yes</td>
<td>1.613</td>
<td>0.490</td>
<td>10.831</td>
<td>5.00 (1.90–13.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Surface water, yes vs no</td>
<td>1.075</td>
<td>0.543</td>
<td>3.918</td>
<td>2.90 (1.01–8.40)</td>
<td>0.048</td>
</tr>
<tr>
<td>Constant</td>
<td>−1.979</td>
<td>0.491</td>
<td>16.251</td>
<td></td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Abbreviations:** ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.
results of different studies, an advanced stage of immunodepression for a CD4 count of <100 cells/mm³ in the present study increased fivefold the risk of opportunistic intestinal parasites.

These findings will have implications for prevention, diagnosis methods, clinical spectra, and treatment among individuals with HIV. The prevention of microsporidia and Cryptosporidium spp. infection via individual and population-based prophylaxis should be established in terms of hygiene. Strict rules should be respected to avoid oro-fecal transmission, including hand washing, washing fresh vegetables, drinking boiled water, and limiting contact with animals susceptible to transmission of microsporidia and Cryptosporidium. The Government of the DRC is encouraged to treat drinking water sources with chloride or ozone. The diagnosis performance of opportunistic intestinal parasites might be established on the basis of the parasitological studies of feces. The genus, genotypes, subgenotypes, and species could be identified by molecular methods in the DRC.

In the treatment of opportunistic intestinal parasites, the following medications are efficient: albendazole, benzimidazole derivatives, fumagillin, nitazoxanide, TNP-470, ovalcin, fluorquinolones, antimototics, polyamine analogs, and interferon gamma. ART should be available for all Congolese HIV patients, as it reduces the viral load and improves CD4 counts, as well as reducing prevalence, morbidity, and mortality related to HIV infection.

This cross-sectional study may be limited to some degree, as the progression of immune status is not precise and, despite the use of PCR methods only for single stool specimens, the prevalence rates of E. bieneusi may be underestimated.

**Conclusion**

The prevalence of E. bieneusi and Cryptosporidium spp. is increasing in Kinshasa, DRC, and the findings of this study recommend epidemiological surveillance and prevention by hygiene. It is necessary to emphasize sensitive PCR methods and to treat microsporidia and Cryptosporidium spp.

**Acknowledgments**

We thank Professor Francis Derouin of the Hospital Saint Louis, Paris, France, and the students of Protestant University of Congo (UPC), Kinshasa, DRC, for sample collection, as well as Mrs Annie Claude Guillo-Olczyk, Isabelle Jolly, Isabelle Meyer, and Liliane Ciceron for excellent technical assistance. We also thank Mr Alain Gaulier and Mrs Mireille Gaulier, Garenne Colombes, France, for social accommodation. We also acknowledge, with thanks, the physician directors and physicians of the four hospitals surveyed for their permission to carry out this study.

**Disclosure**

The authors have not received any funding or benefits from any industry, financing agency, or elsewhere, to conduct this study and report no conflicts of interest in this work.

**References**


Microsporidiosis and cryptosporidiosis among HIV/AIDS patients